Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.
Weam Othman ElbezantiKishore B ChallagundlaSubash C JonnalagaddaTulin Budak-AlpdoganManoj K PandeyPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.
Keyphrases
- end stage renal disease
- free survival
- multiple myeloma
- bone marrow
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- mesenchymal stem cells
- current status
- young adults
- papillary thyroid
- patient reported outcomes
- lymph node metastasis
- replacement therapy
- childhood cancer